| Literature DB >> 30922138 |
Zhuo Liu1, Shiying Tang1, Xiaojun Tian1, Shudong Zhang1, Guoliang Wang1, Hongxian Zhang1, Lulin Ma1.
Abstract
OBJECTIVE: To simplify Foley catheter-assisted thrombectomy to a six-step approach and determine the feasibility and results of this technique for renal cell carcinoma (RCC) with a Mayo level II to IV tumor thrombus (TT).Entities:
Keywords: Foley catheter-assisted six-step thrombectomy; Inferior vena cava; Mayo level; renal cell carcinoma; surgical technique; tumor thrombus
Mesh:
Year: 2019 PMID: 30922138 PMCID: PMC6567778 DOI: 10.1177/0300060519836912
Source DB: PubMed Journal: J Int Med Res ISSN: 0300-0605 Impact factor: 1.671
Patients’ clinicopathological and operative characteristics.
| Variables | Value |
|---|---|
| Number of patients | 15 |
| Age, years | 52.2 ± 22.4 (median, 59.0) |
| Sex | |
| Male | 10 (66.7) |
| Female | 5 (33.3) |
| Body mass index, kg/m2 | 21.9 ± 3.1 |
| Mayo clinic TT level | |
| II | 3 (20.0) |
| III | 7 (46.7) |
| IV | 5 (33.3) |
| Preoperative serum Cr, µmol/L | 93.7 ± 29.3 |
| Postoperative serum Cr, µmol/L | 132.0 ± 178.8 |
| Location | |
| Left | 5 (33.3) |
| Right | 10 (66.7) |
| Tumor size, cm | 8.7 ± 2.5 |
| ASA score, n(%) | |
| I | 1 (6.7) |
| II | 8 (53.3) |
| III | 5 (33.3) |
| IV | 1 (6.7) |
| Operation time, minutes | 420.1 ± 108.9 |
| Intraoperative blood loss, mL | 1846.7 ± 1467.8 |
| Perioperative red blood cell transfusion, mL | 1288.7 ± 1060.6 |
| Lymphadenectomy | |
| No | 7 (46.7) |
| Yes | 8 (53.3) |
| Adrenalectomy | |
| No | 5 (33.3) |
| Yes | 10 (66.7) |
| Histology | |
| Clear cell RCC | 9 (60.0) |
| Papillary RCC | 3 (20.0) |
| Nephroblastoma | 2 (13.3) |
| Xp11.2 translocation/ TFE3 gene fusion RCC | 1 (6.7) |
| WHO/ISUP grading system | |
| 2 | 2 (13.3) |
| 3 | 8 (53.3) |
| 4 | 3 (20.0) |
| n/a | 2 (13.3) |
| Clavien classification | |
| <III | 13 (86.7) |
| ≥III | 2 (13.3) |
| Length of hospital stay, days | 13.1 ± 4.4 (median, 13) |
| Follow-up time, months | 9 (0–34) |
| Local recurrence | |
| No | 14 (93.3) |
| Yes | 1 (6.7) |
| Distant metastasis | |
| No | 12 (80.0) |
| Yes | 3 (20.0) |
| Adjuvant therapy | |
| No | 7 (46.7) |
| Yes | 8 (53.3) |
Data are presented as n (%), mean ± standard deviation, or median (range).
TT, tumor thrombus; Cr, creatinine; ASA, American Society of Anesthesiologists; RCC, renal cell carcinoma; WHO, World Health Organization; ISUP, International Society of Urological Pathology.
Patients’ clinicopathological and operative characteristics in detail.
| Number | Sex | Age (years) | BMI (kg/m2) | Mayo TT classification | Preoperative serum Cr (µmol/L) | Side | Tumor size (cm) | ASA score | Duration of surgery (minute) | Intraoperative blood loss (mL) | Perioperative red blood cell transfusion (mL) | Adrenalectomy |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Male | 62 | 23.3 | IV (enter the atrium) | 126 | Left | 5.8 | 3 | 589 | 2800 | 3200 | Yes |
| 2 | Female | 63 | 22.4 | II | 153 | Right | 6.2 | 2 | 258 | 300 | 400 | No |
| 3 | Female | 52 | 19.9 | III | 82 | Right | 8.3 | 2 | 272 | 1550 | 1200 | Yes |
| 4 | Male | 57 | 21.0 | IV | 92 | Left | 6.9 | 2 | 558 | 2000 | 1200 | Yes |
| 5 | Male | 50 | 24.8 | III | 85 | Right | 5.8 | 3 | 374 | 300 | 0 | Yes |
| 6 | Male | 71 | 28.0 | III | 133 | Right | 7.2 | 3 | 372 | 3000 | 1600 | Yes |
| 7 | Male | 2.5 | 17.3 | II | 43 | Right | 8.4 | 2 | 248 | 50 | 130 | No |
| 8 | Male | 59 | 23.4 | III | 108 | Right | 10.0 | 3 | 445 | 1500 | 1200 | Yes |
| 9 | Male | 69 | 22.0 | II | 122 | Right | 10.0 | 3 | 435 | 4000 | 2400 | Yes |
| 10 | Female | 55 | 24.8 | III | 79 | Left | 8.3 | 2 | 541 | 3000 | 1600 | Yes |
| 11 | Male | 68 | 21.7 | III | 84 | Right | 7.6 | 2 | 376 | 2000 | 2000 | Yes |
| 12 | Female | 69 | 25.1 | IV (enter the atrium) | 67 | Left | 10.9 | 2 | 515 | 5000 | 3200 | Yes |
| 13 | Female | 15 | 17.3 | III | 67 | Right | 13.0 | 1 | 372 | 600 | 0 | No |
| 14 | Male | 74 | 19.1 | IV | 75 | Left | 7.5 | 2 | 443 | 800 | 400 | No |
| 15 | Male | 17 | 18.9 | IV | 89 | Right | 14.0 | 4 | 504 | 800 | 800 | No |
TT, tumor thrombus; Cr, creatinine; ASA, American Society of Anesthesiologists; WHO, World Health Organization; ISUP, International Society of Urological Pathology.
| Number | Histology | 2016WHO/ISUP grading system | Hospital stay (days) | Postoperative serum Cr at 1 week (µmol/L) | Complication | Clavien classification | Survival status | Local recurrence | Distant metastasis | Adjuvant therapy |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Clear cell RCC | 3 | 14 | 86 | Dead | V | Dead | No | No | No |
| 2 | Clear cell RCC | 2 | 9 | 125 | – | – | Alive | No | No | Targeted therapy |
| 3 | Clear cell RCC | 3 | 14 | 94 | – | – | Dead | Yes | Lung | No |
| 4 | Papillary RCC | 3 | 9 | 111 | – | – | Alive | No | Lung | Targeted therapy |
| 5 | Clear cell RCC | 3 | 13 | 116 | Venous thrombosis of lower extremities | II | Alive | No | No | Targeted therapy |
| 6 | Clear cell RCC | 3 | 12 | 112 | – | – | Loss | No | No | No |
| 7 | NB | n/a | 15 | 32 | Pulmonary infection | II | Alive | No | No | Targeted therapy |
| 8 | Papillary RCC | 2 | 10 | 87 | – | – | Dead | No | No | Targeted therapy |
| 9 | Clear cell RCC | 4 | 9 | 772 | Anemia and renal failure | IVa | Dead | No | No | No |
| 10 | Clear cell RCC | 4 | 17 | 79 | – | – | Loss | No | No | No |
| 11 | Papillary RCC | 3 | 15 | 75 | Anemia | II | Alive | No | No | Targeted therapy |
| 12 | Clear cell RCC | 3 | 25 | 85 | – | – | Alive | No | Lung | No |
| 13 | Xp11.2 translocation/TFE3 gene fusion RCC | 4 | 14 | 48 | – | – | Alive | No | No | Targeted therapy |
| 14 | Clear cell RCC | 3 | 7 | 93 | – | – | Alive | No | No | Targeted therapy |
| 15 | NB | n/a | 13 | 65 | – | – | Alive | No | No | No |
TT, tumor thrombus; Cr, creatinine; ASA, American Society of Anesthesiologists; WHO, World Health Organization; ISUP, International Society of Urological Pathology; NB, nephroblastoma.